Bayer is investing over €500m ($700m) in manufacturing recombinant factor VIII (rFVIII) products citing growing demand for long-term prophylactic treatment rather than ‘on-demand’ haemophilia drugs.
Ireland is seeing a renewed interest from biotech, the Industrial Development Agency (IDA) says, as Bristol-Myers Squibbs shuts a Dublin API plant to focus on biopharmaceuticals.
The new Centre for Cell Manufacturing Ireland (CCMI) in Galway means Ireland-based scientists will be able to manufacture culture-expanded stem cells for drug research for the first time.
Industry group BIO has responded to a petition by the Generic Pharmaceutical Association (GPhA) in the latest bout of the debate over the international non-proprietary name (INN) for biosimilars.
Biologics could be delivered by routes other than injection using nanobodies one tenth the size of an antibody, Ablynx says as it extends its license with Merck & Co.
Biosimilars could save the US healthcare budget a quarter of a trillion dollars, says Hospira who expects to submit its first application to the USFDA within a year.
The evaluation of Genmab’s Duobody platform for the discovery and development of bispecific antibodies strengthens Eli Lilly’s biologics programme, the firm says.
Johnson & Johnson (J&J) has called on the US FDA to prevent biosimilars being given the same non-proprietary names as their original biologics, while the European Generics Association maintains the practice is “proven to be safe” and “supported...
AstraZeneca has become the third Big Biopharma to strike a deal with Immunocore to license its Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology.
